News and publications
Search & filter
Filter by Content Type
Looking back and moving forward: A year of progress for MPN PROGRESSion Registry®
September 26th marked an important milestone: the first anniversary of the MPN PROGRESSion Registry® launch. The Registry is a collaborative, patient-focused research initiative working to collect comprehensive myeloproliferative neoplasm (MPN) patient health data and self-reported surveys over a 5-10 year period. The goals of the study are to help scientists and clinicians better understand the causes of MPN disease progression, identify new treatments, assess efficacy of care strategies, and support the development of globally recognized endpoints.
Four Recent MPN Milestones Point to a Bigger Question: How Do We Measure Meaningful Progress?
The pace of innovation in myeloproliferative neoplasms (MPNs) continues to accelerate. Within a matter of weeks, the MPN community has seen a new Federal Drug Administration (FDA) approval for polycythemia vera (PV), an expanded indication for essential thrombocythemia (ET), a major manufacturing milestone affecting treatment access, and a regulatory filing that may further expand options for patients with myelofibrosis (MF).
Taken together, these developments reflect a field that is advancing on multiple fronts at once. They also highlight a broader question facing patients, clinicians, researchers, regulators, and industry alike.
From collaboration to publication: How the Progression Research Network is advancing MPN progression research
One of the greatest challenges in myeloproliferative neoplasm (MPN) research is understanding why some patients experience disease progression and how that progression can be identified earlier and more accurately. While physicians can recognize advanced disease states, researchers are still working to determine which early biological changes signal or predict progression.
From Scientific Breakthroughs to Patient Care: How Dr. John Mascarenhas Is Advancing MPN Research and Care
Scientific breakthroughs do not become medicines on their own. They require physician-scientists who can recognize a promising discovery, work with laboratory researchers and industry partners to test it rigorously and guide it through the long path toward patient care.
Dr. John Mascarenhas, MD, has spent his career doing exactly that. For more than two decades, he has worked at the intersection of laboratory discovery and patient care, helping transform scientific ideas into treatments that now change lives.
Patient Stories: Ensuring MPNs are seen, understood, and never forgotten
One patient hoped to bring a few dozen people together and instead saw over 200 join in person and online. Another told his MPN story to strangers around the world and watched as they began telling stories of their own. A third transformed a personal connection into a grassroots fundraising effort that rallied friends, family, and supporters to invest in research when time was running out. Their approaches were different, but their goal was the same: to ensure that MPNs are seen, understood, and never forgotten.
Where MPN researchers begin: Inside Aishwarya Krishnan’s path through graduate school and MPN research
A 7-minute walk does not sound difficult until it is January in St. Louis. For graduate student Aishwarya Krishnan, that trek through wind, snow, and slush leads to the mouse facility where long experimental days begin and where the next generation of blood cancer research is taking shape.
The many paths of MPNs: New research explores the various genetic paths of patients
Myeloproliferative neoplasms (MPNs) are rare blood cancers that often unfold slowly. Some people live with stable disease for many years, while others experience progression to myelofibrosis or acute myeloid leukemia (AML). Understanding why these paths differ is a central challenge in MPN research.
A new study, Genomic evolution and natural history of myeloproliferative neoplasms on therapy, led by researchers including Dr. Jyoti Nangalia, takes a long view of this question (Leongamornlert et al., 2026). The project tracks how the genetic makeup of MPN patients change over time and across diagnoses.
EHA & ASCO clinical trial read outs: How these impact patient quality of life
The thrill that drives researchers: Dr. Josef Prchal on ambition, competition, and the [selfish] joy of discovery
he road to scientific discovery is littered with disappointment. For researchers like Dr. Josef Prchal, MD, the moments that make the journey worthwhile are not a guaranteed outcome or incremental progress; it is the rare, intoxicating thrill of finding something no one has seen before.
Honoring Dr. Richard T Silver, MD
Few individuals have shaped the myeloproliferative neoplasm (MPN) field as steadily and thoughtfully as Dr. Richard T. Silver, MD, FACP, whose career exemplified the power of patience, independence, and long‑term scientific commitment. Over decades, he helped move the field forward by asking difficult questions early, standing by promising science long before it gained consensus, and contributing to standards of research, care, and collaboration that continue to shape how MPNs are understood today.
MPN Research Foundation (MPNRF) and Canadian MPN Research Foundation (CMPNRF) launch collaboration to improve outcomes for MPN patients
MPN Research Foundation and Canadian MPN Research Foundation are pleased to announce a new collaboration focused on improving outcomes for myeloproliferative neoplasm (MPN) patients in the U.S., Canada, and beyond. The goal of the strategic initiative is to combine expertise and resources and work together to fund and support research leading to new and better treatments and possible cures for these diseases.
The power of persistence: MPN researchers honored with Ernest Beutler Prize at ASH 2025
Inside the Orlando Convention Center, a room as vast as an airline hangar was bathed in green light from numerous two-story-high screens. Thousands of hematology researchers filled the space, waiting for a marquee lecture.